Zurich, January 31, 2026, 20:21 CET — Trading wrapped up
- Novartis’ U.S.-listed ADRs (NVS) ended Friday at $148.68, slipping roughly 0.1%
- Swiss drugmaker set to release its Q4 and full-year 2025 earnings on Feb. 4
- Analysts are zeroing in on key brand sales trends and 2026 guidance to gauge the next move
Novartis AG’s U.S.-listed ADRs — representing the Swiss shares — dipped 0.1% on Friday, closing at $148.68 after fluctuating between $148.05 and $149.89. Roughly 1.15 million ADRs were traded.
Markets are closed for the weekend, shifting focus to Novartis’ next update. The investor calendar pins February 4 for the fourth-quarter and full-year 2025 results, alongside the Annual Report 2025 release. A webcast is scheduled from Basel, Switzerland, at 14:00 CET. (Novartis)
Zacks Investment Research’s Nasdaq forecasts project quarterly earnings at $1.99 per share on $13.72 billion in revenue. The same report highlights analyst estimates for Cosentyx U.S. revenue at $1.02 billion and Entresto U.S. revenue at $450.8 million, marking a 63.8% drop year-over-year. It also places Cosentyx revenue outside the U.S. (ROW) at roughly $636.9 million. (Nasdaq)
Traders are focused on one clear event: the Feb. 4 print. Until then, ADRs will mostly move with the broader risk mood and any shifts ahead of earnings.
Investors are keenly awaiting management’s comments on the 2026 outlook. When there’s no new headline to move the stock, guidance on sales growth, margins, and cash returns usually carries the weight.
Colour varies by drug this time around. Cosentyx, used for psoriasis and arthritis, continues to deliver steady growth. Entresto stays crucial for heart failure. Meanwhile, oncology meds like Tafinlar and Mekkinist can shift the quarterly balance significantly.
Investors will be closely tracking any tweaks to the company’s R&D schedule and regulatory strategy, even if the updates are vague. Minor adjustments in timing often carry more weight than the presentation itself.
Much of the near-term optimism depends on flawless execution. Should major brands fall short of sales targets or management adopt a cautious stance on 2026, the stock might slide sharply following a subdued end to the week.
Trading picks up again Monday, but the big moment is yet to come. The next key event is the February 4 results announcement and webcast from Basel at 14:00 CET. Investors will be focused on the guidance and the Q&A session that follows.
